CYP interactions Flashcards
Fluvoxamine
Strong inhibitor *1A2 /2C19
Mod inhibitor 2C9/ *3A4
Substrate: 2D6, 1A2
Fluoxetine
Norfluoxetine
FLUOXETINE:
Strong inhibitor 2D6
substrate: 2D6
NORFLUOXETINE (active metabolite)
Mod inhibitor 3A4
Paroxetine
Strong inhibitor *2D6
Weak inhibitor *2C9 and 2C19
Substrate: 2D6
note* carbamazepine reduces paroxetine levels by 28%
Sertraline
Mod inhibitor 2D6
Substrate: 3A4, 2D6, 2C19, 2C9
Citalopram, Escitalopram
Substrate: 2C19
Venlafaxine
Desvenlafaxine
Venlafaxine:
Mild inhibitor 2D6
Substrate: 3A4, 2D6
Desvenlafaxine: active metabolite, not metabolized by 2D6
Duloxetine
moderate inhibitor 2D6
Substrate: 2D6
Buproprion
Mod inhibitor 2D6
Substrate: 2B6 (not D)
Mirtazapine
Substrate: 2D6, 3A4, and (lesser extent) 1A2
Meds that decrease epival levels
Carbamazepine (tegretol)
+ Phenytoin (dilantin)
Phenobarbital
Rifampin
Lamotrigine decreases VPA by 25%
Meds that increase epival
ASA + Ibuprofen
Chlopromazine
Luvox + Prozac + Amitryptyline
Topiramate
Erythromycin
Epival increases levels of:
Lamotrigine x2
Dilantin
Diazepam
No interaction with OCP
Clomipramine & TCAs
Phenobarbital
Clomipramine Luvox interaction
Luvox inhibits metabolism clomipramine via CYPA 1 A2
Epival & Phenobarbital interaction
Phenobarbital decreases epival levels
Epival increases phenobarbital levels via CYP2C9
Epival in pregnancy - % neural tube defects, spinal bifida
Neural tube defects = 5%
Spina bifida = 1-2 %